#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Michael Gilman Email
CEO . Arrakis Therapeutics
How to contact Michael Gilman
Join and see Michael's contact info for free!Current Roles
Employees:
119Revenue:
$23.9MAbout
Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. The company's TRYST and PEARL-seq platforms identify new RNA targets and drug candidates to treat diseases unaddressed by today's medicines. Arrakis is developing a proprietary pipeline of RNA-targeted small molecules focused on neurologic diseases, cancer, and rare genetic diseases. Arrakis was founded in 2015 by Russell Petter, Ph.D., Alan Walts, Ph.D., Henri Termeer and Raj Parekh, Ph.D. with a vision to create a proprietary, transformational discovery platform that identifies small-molecule drugs that act directly on disease-causing RNA. The company was established with seed funding provided by Advent Life Sciences and Henri Termeer. The company brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life sciences investors. The company is located in Waltham, Mass.Arrakis Therapeutics Address
828 Winter StreetWaltham, MA
United States